Jagsonpal Pharma Promoters Declare No Share Encumbrance as of March 31, 2026
Promoters and persons acting in concert of Jagsonpal Pharmaceuticals Limited, including Infinity Holdings and Rajpal Singh Kochhar, have declared no encumbrance on their shares as of March 31, 2026. Disclosures were made to BSE and NSE on April 6-9, 2026.
This is a standard disclosure under SEBI Takeover Regulations, confirming no encumbrance on shares, which is a routine event for promoters and does not indicate any significant change in shareholding structure or control.
The announcement is a routine regulatory filing regarding share encumbrance, with no positive or negative financial or business developments reported.
Jagsonpal Pharmaceuticals Limited has submitted disclosures under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, for the financial year ended March 31, 2026. Various promoters and persons acting in concert, including Infinity Holdings, Rajpal Singh Kochhar, and Aresko Progressive Private Limited, have declared that no shares of the company have been encumbered, directly or indirectly, during this period.
The disclosures were made to the BSE Ltd and the National Stock Exchange of India Ltd on April 06, 2026, and April 09, 2026, respectively. The company, through its Company Secretary and Compliance Officer Pratham Rawal, has requested that these disclosures be taken on record.
Annexure A lists the various entities and individuals considered as promoters and promoter group, including Infinity Holdings, Rajpal Singh Kochhar, Prithipal Singh Kochhar, Inderpal Singh Kochhar, and numerous other entities such as Aresko Progressive Private Limited, Aresko Life Sciences Private Limited, and various Aresko and Sewara entities, all of whom have confirmed no encumbrance on their shares.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.